Released Nov 9, 2023, before the open
10-Q filed Nov 9, 2023, 40 days after period end · 0001171843-23-006912
Q3 2023 · 10-Q
Revenue$0.00$0.00 no prior Q3 2022 on fileno prior Q2 2023 on file
Net Income-$9.96M-$9.96M N/M vs Q3 2022N/M vs Q2 2023
EPS, diluted—
Operating Income-$11,926,000N/M
Operating Cash Flowderived-$5,922,000N/M
Free Cash Flowderived-$5,932,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$9.96M | -$11.98M | -$5.98M | -$9.15M |
| EPS Diluted | — | — | -$0.10 | -$0.18 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR